Dynavax Technologies

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Dynavax Technologies reports strong Q4 earnings, eyes continued growth

Dynavax Technologies showcased robust financial performance, driven by the success of HEPLISAV-B and CpG 1018 adjuvant. Progress in clinical development and market share growth were notable achievements. Challenges include maintaining market growth amidst competition and regulatory changes, while opportunities exist in expanding product revenue and advancing vaccine programs.

Dynavax reports record revenue growth, eyes market expansion opportunities

Dynavax Technologies showcased robust performance in Q1 2023, driven by record revenue growth and strong financial results.
While facing challenges such as uncertainties and competition, the company's strategic strengths and opportunities position it for continued success.
Management's focus on innovation, market expansion, and financial stability bodes well for future growth and shareholder value.
Overall, Dynavax Technologies remains optimistic about its outlook, supported by a dedicated team and a solid commercialization strategy.

Dynavax reports strong Q2 earnings, eyes growth through innovation

Dynavax Technologies delivered robust financial results in Q2 2023, driven by strong HEPLISAV-B revenue growth and increased market share.
The company's focus on innovation, market expansion, and financial stability positions it well for future growth and strategic opportunities.
While facing challenges in revenue sustainability and competition, Dynavax's strengths in market penetration and product pipeline offer avenues for continued success.
By leveraging opportunities in market expansion, product diversification, and strategic partnerships, Dynavax can further solidify its position in the vaccine and infectious disease spaces.

Dynavax reports record revenue growth and raises full-year guidance

Dynavax Technologies delivered a strong performance in Q3 2023, driven by record HEPLISAV-B revenue and market share gains.
While facing margin pressures from increasing expenses, the company's strategic focus on diversification and innovation bodes well for future growth.
With raised revenue guidance, a robust clinical pipeline, and a solid financial position, Dynavax is poised for continued success and market expansion.

Dynavax Technologies reports record revenue growth and strategic investments

Dynavax Technologies' Q4 2023 earnings call highlighted robust revenue growth, market leadership, and strategic investments in HEPLISAV-B.
The company's financial outlook for 2024, including revenue guidance and expense projections, reflects a balanced approach to growth and profitability.
With a strong cash position, ongoing pipeline developments, and focus on cost management, Dynavax is poised for continued success and market expansion.

Dynavax Technologies reports robust Q1 earnings and growth outlook

Dynavax Technologies delivered solid financial results in Q1 2024, driven by continued growth in HEPLISAV-B net product revenue and a focus on innovation and R&D advancement.
Despite market challenges and expenses, the company's strong cash position, market leadership, and upcoming milestones position it well for sustainable growth and success.
With a clear strategic focus on driving growth, maintaining market share, and advancing its vaccine portfolio, Dynavax is poised for a promising future in the healthcare industry.

Dynavax reports record sales and market share gains in Q2 2024

Dynavax Technologies delivered strong financial performance in Q2 2024, driven by record HEPLISAV-B sales and market share gains.
The company's pipeline progress and robust cash position position it well for future growth and innovation.
While challenges in managing expenses persist, strategic opportunities and a positive outlook for HEPLISAV-B offer avenues for sustained success.
Dynavax's focus on cost management, market expansion, and product development will be key to capitalizing on opportunities and overcoming challenges.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

-- SCB-2019 (CpG 1018/Alum) elicited approximately 2-fold higher neutralizing antibody titers in adolescents (aged 12 to 17 years) compared to young adults (aged 18 to 25 years) -- -- Favorable tolerability and safety profile in adolescents, consistent with results previously observed in adults --

Clover Announces Positive Phase 2/3 Results in Adolescents for its COVID-19 Vaccine

Valneva SE

Saint-Herb lain (France) , August 2 3 , 2 02 2 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, confirms today that the World Health Organization (WHO) has issued recommendations for use of the Company's inactivated COVID-19 vaccine.

Valneva Confirms WHO Recommendations for its Inactivated COVID-19 Vaccine

When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?

Dynavax Technologies (DVAX) Recently Broke Out Above the 20-Day Moving Average

The average of price targets set by Wall Street analysts indicates a potential upside of 92.2% in Dynavax Technologies (DVAX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in Dynavax Technologies (DVAX)? Wall Street Analysts Think 92%

The company delivered resounding beats on both the top and bottom lines in the second quarter.

Why Dynavax Stock Was Crushing It on Friday

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 290.91% and 73.80%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Dynavax Technologies (DVAX) Q2 Earnings and Revenues Beat Estimates

Dynavax Technologies Corporation (NASDAQ:DVAX ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Nicole Arndt – Senior Manager for Investor Relations Ryan Spencer – Chief Executive Officer Donn Casale – Senior Vice President of Commercial Rob Janssen – Chief Medical Officer Kelly MacDonald – Chief Financial Officer Conference Call Participants Ernesto Rodriguez-Dumont – Cowen Matthew Phipps – William Blair Edward White – H.C. Wainwright Operator Good day and welcome to the Dynavax Technologies' Second Quarter 2022 Financial Results Call.

Dynavax Technologies Corporation (DVAX) CEO Ryan Spencer on Q2 2022 Results - Earnings Call Transcript

Q2 2022 total revenue of $256.5 million, up 386% from $52.8 million for Q2 2021 HEPLISAV-B ®  vaccine net product revenue of $32.7 million, up 139% from $13.7 million for Q2 2021 CpG 1018 ® adjuvant net product revenue of $222.6 million, up 471% from $39.0 million for Q2 2021 On track for second consecutive year of profitability Conference call today at 4:30 p.m. ET/1:30 p.m.

Dynavax Reports Second Quarter 2022 Financial Results

Saint- Herb lain (France ) , August 1 , 2 02 2 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today confirms the signing of the amendment to its Advance Purchase Agreement (APA)1 with the European Commission (EC), following expiration of the Member States' opt-out period, as announced by the Company on July 20, 20222. Under this amendment, the Member States' purchases of VLA2001, Valneva's inactivated whole-virus COVID-19 vaccine, consist of 1.25 million doses of VLA2001 in 2022, with the option to purchase an equivalent quantity later this year for delivery in 2022.

Valneva Confirms Amendment of Advance Purchase Agreement with European Commission for Valneva's Inactivated COVID-19 Vaccine

EMERYVILLE, Calif. , July 21, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report second quarter financial results on Thursday, August 4, 2022, after the U.S. financial markets close.

Dynavax to Report Second Quarter Financial Results and Host Conference Call on August 4, 2022

The mean of analysts' price targets for Dynavax Technologies (DVAX) points to an 111.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See an 111% Upside in Dynavax Technologies (DVAX): Can the Stock Really Move This High?

European Commission to order 1.25 million doses of Valneva's whole-virus COVID-19 vaccine VLA2001 in 2022

European Commission Approves Purchase Agreement Amendment for Valneva's Inactivated COVID-19 Vaccine

Arch Resources

Avantis U.S. Small Cap Value ETF

CONSOL Energy

Coursera

Fate Therapeutics

Tenable Holdings Inc

These are the best small-cap stocks to buy for July 2022. ARCH, AVUV, CEIX, COUR, DVAX, FATE, and TENB can make great investments.

7 Small-Cap Stocks to Buy in July 2022

SHANGHAI, China, June 27, 2022 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced new positive clinical data in individuals vaccinated with a third dose of SCB-2019 (CpG 1018/Alum) as a homologous booster against the Omicron variant. A homologous booster dose of SCB-2019 (CpG 1018/Alum) demonstrated a significant, 19-fold increase in neutralizing antibody levels against the Omicron BA.2 variant compared to pre-booster levels among baseline seronegative participants.

Clover's COVID-19 Vaccine Candidate Demonstrates Strong Cross-Neutralization Against Omicron as a Homologous Booster

VLA2001 becomes the first COVID-19 vaccine to receive a standard marketing authorization in Europe

Valneva Receives Marketing Authorization in Europe for Inactivated Whole-Virus COVID-19 Vaccine VLA2001

Its partner's coronavirus vaccine comes one important step closer to approval in Europe.

Why Dynavax Crushed the Market on Thursday

Saint Herblain (France ), June 23 , 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization in Europe for Valneva's inactivated whole-virus COVID-19 vaccine candidate, VLA2001, for use as primary vaccination in people from 18 to 50 years of age.

Valneva Receives Positive CHMP Opinion for Marketing Authorization of its Inactivated COVID-19 Vaccine Candidate in Europe

Saint- Herb lain (France ) , June 15 , 202 2 – Valneva SE, (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has entered into a settlement agreement with the Government of the United Kingdom (“HMG”) in relation to the termination of the supply agreement for Valneva's COVID-19 vaccine candidate, VLA2001.

Valneva Announces Settlement Agreement with the UK Government

-- Study to evaluate SCB-2019 (CpG 1018/Alum) as a heterologous booster in individuals previously vaccinated with CoronaVac™  ( Sinovac Inactivated Vaccine ), Comirnaty ® ( Pfizer mRNA Vaccine ), and Vaxzevria ® ( AstraZeneca Viral Vector Vaccine ) -- -- Safety & immunogenicity data expected for key 3 rd dose booster groups (CoronaVac™  and Comirnaty ® ) in Q3-2022 and the 4 th dose booster group (CoronaVac™ ) in Q4-2022 --

Clover Doses First Participants in Phase 3 Trial Evaluating SCB-2019 as a Heterologous COVID-19 Booster Following Prior Vaccination with Inactivated, mRNA or Viral Vector Vaccines

Saint-Herb lain (France ) , June 1 0 , 2 02 2 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today provides an update on its European inactivated whole-virus COVID-19 vaccine candidate VLA2001. Following receipt of the European Commission (EC)'s notice of intent to terminate the Advance Purchase Agreement (APA)1, Valneva proposed a remediation plan, which is now subject to further discussion within the EC and among the participating member states.

Valneva Provides Update on European Inactivated, Whole-Virus COVID-19 Vaccine Program VLA2001

EMERYVILLE, Calif. , May 25, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Ryan Spencer , Chief Executive Officer and Kelly MacDonald , Chief Financial Officer, will participate in a fireside chat during the William Blair 42nd Annual Growth Stock Conference in Chicago, Illinois on Monday June 6, 2022 at 4:40 p.m.

Dynavax to Present at the William Blair 42nd Annual Growth Stock Conference

DVAX will do well as long as the coronavirus vaccine demand exists. While the urgency is somewhat abated, an evolving endemic situation may continue to need CpG 1018.

Dynavax: Evolving Endemic Situation Adds To Its Risk

Dynavax (DVAX) gains as the EMA accepts partner Valneva's MAA for COVID-19 vaccine.

Dynavax (DVAX) Up as EMA Accepts Valneva's COVID-19 Vaccine MAA

One of its vaccine partners had some encouraging regulatory news to report.

Why Dynavax Stock Blasted 16% Higher Today

The company earns an Emergency Use Authorization from a well-off Middle Eastern country.

News for Dynavax Technologies Stock (DVAX)